Matches in Wikidata for { <http://www.wikidata.org/entity/Q90927575> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- Q90927575 description "article scientifique publié en 2019" @default.
- Q90927575 description "artículu científicu espublizáu n'ochobre de 2019" @default.
- Q90927575 description "scientific article published on 22 October 2019" @default.
- Q90927575 description "wetenschappelijk artikel" @default.
- Q90927575 description "наукова стаття, опублікована 22 жовтня 2019" @default.
- Q90927575 name "Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM)" @default.
- Q90927575 name "Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM)" @default.
- Q90927575 type Item @default.
- Q90927575 label "Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM)" @default.
- Q90927575 label "Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM)" @default.
- Q90927575 prefLabel "Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM)" @default.
- Q90927575 prefLabel "Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM)" @default.
- Q90927575 P1433 Q90927575-B41051AD-D818-48B2-A1EF-0614EB218C3C @default.
- Q90927575 P1476 Q90927575-C4AA72DE-3890-4E28-8A86-52D6F4C23B5E @default.
- Q90927575 P2093 Q90927575-086E75BF-90FD-4F87-93C4-3EC4EBEB40C4 @default.
- Q90927575 P2093 Q90927575-186B8060-AA46-4387-AD38-0B83F1E42DF3 @default.
- Q90927575 P2093 Q90927575-3A9EBC5F-8525-4B80-A576-1969D29BDED9 @default.
- Q90927575 P2093 Q90927575-3BE9FD3F-7FA3-41EF-BCF1-CE4BF5C23AA7 @default.
- Q90927575 P2093 Q90927575-4268485A-7C57-4654-B9A8-2429071A799F @default.
- Q90927575 P2093 Q90927575-4C5A2B10-5420-4D07-A828-FA01F34D6E7B @default.
- Q90927575 P2093 Q90927575-6BCACF1C-36FE-44CC-A089-EB4BD4EF10C8 @default.
- Q90927575 P2093 Q90927575-7044E980-1B52-43CE-87C4-6A4EF61D5763 @default.
- Q90927575 P2093 Q90927575-7531F201-F71B-478C-80BD-DE2768451B6B @default.
- Q90927575 P2093 Q90927575-8CFF0D0E-7FBF-4CAB-A3A9-F901F594FFA6 @default.
- Q90927575 P2093 Q90927575-A0C7E683-490E-4B63-A7E1-A56F4CFD9DF7 @default.
- Q90927575 P2093 Q90927575-BAE9080A-4190-4172-8C59-4EA44FBFFE32 @default.
- Q90927575 P2093 Q90927575-BE9C87C4-5E77-4CEA-9AAB-528985778347 @default.
- Q90927575 P2093 Q90927575-CD749806-9D97-4D43-9391-4DEE302CD1A7 @default.
- Q90927575 P2093 Q90927575-CFA9CF37-3E5C-45C5-8791-679409148BEE @default.
- Q90927575 P2093 Q90927575-D8CD4C70-BB6B-4438-9E3C-D04737A262F7 @default.
- Q90927575 P2093 Q90927575-E095ACD1-351A-4C8F-BC4C-3F7516FC05BD @default.
- Q90927575 P304 Q90927575-0F2D4863-16AB-4A16-82BB-6650CEDDD853 @default.
- Q90927575 P31 Q90927575-E179C45A-354B-4A5C-9286-EBBFAC7CD50B @default.
- Q90927575 P356 Q90927575-C6B58792-31A9-4294-87FD-912FA9D8A2CD @default.
- Q90927575 P478 Q90927575-A8B4FE9A-4CF5-42A1-8AB7-971CF71F31D7 @default.
- Q90927575 P577 Q90927575-E1F0B606-AEA2-46E9-8514-5646E42ABF6F @default.
- Q90927575 P698 Q90927575-9789C2DC-53A7-41D8-8055-F6E94191BF85 @default.
- Q90927575 P921 Q90927575-6FE3DDE1-735C-4CC3-926C-877AC712592C @default.
- Q90927575 P356 J.EJCA.2019.08.033 @default.
- Q90927575 P698 31648851 @default.
- Q90927575 P1433 Q332260 @default.
- Q90927575 P1476 "Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM)" @default.
- Q90927575 P2093 "Anders Ullén" @default.
- Q90927575 P2093 "Andreas Carus" @default.
- Q90927575 P2093 "Camilla Mellnert" @default.
- Q90927575 P2093 "Cecilia Nilsson" @default.
- Q90927575 P2093 "Elisabeth Öfverholm" @default.
- Q90927575 P2093 "Erika Jonsson" @default.
- Q90927575 P2093 "Hans von der Maase" @default.
- Q90927575 P2093 "Helle Pappot" @default.
- Q90927575 P2093 "Hemming Johansson" @default.
- Q90927575 P2093 "Karin Holmsten" @default.
- Q90927575 P2093 "Lene Sonne Mouritsen" @default.
- Q90927575 P2093 "Mads Agerbæk" @default.
- Q90927575 P2093 "Mats Hellström" @default.
- Q90927575 P2093 "Mette Moe" @default.
- Q90927575 P2093 "Niels Viggo Jensen" @default.
- Q90927575 P2093 "Outi Lahdenperä" @default.
- Q90927575 P2093 "Yvonne Brandberg" @default.
- Q90927575 P304 "173-182" @default.
- Q90927575 P31 Q13442814 @default.
- Q90927575 P356 "10.1016/J.EJCA.2019.08.033" @default.
- Q90927575 P478 "127" @default.
- Q90927575 P577 "2019-10-22T00:00:00Z" @default.
- Q90927575 P698 "31648851" @default.
- Q90927575 P921 Q42824440 @default.